Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.02.06.704498

Targeting Myc activates a tissue-specific tumour resolution programme

Abstract

Neoplastic transformation parallels hallmark cellular programs of tissue regeneration and wound repair1,2. However, the mechanisms driving tumour regression upon oncogenic driver inhibition--and why it often fails--remain poorly understood3-7. Oncogenic KRas mutations and Myc deregulation, two archetypal cancer drivers, frequently occur and cooperate to promote aggressive lung adenocarcinoma (LUAD)8-12. To investigate the mechanistic consequences of targeting Myc in LUAD, we applied spatiotemporally controlled genetic and functional perturbations in a reversible KRas/Myc-driven mouse model, integrated with RNA sequencing and immune protein profiling of tumours and their microenvironment. Acute oncogenic Myc inactivation in epithelial tumour cells elicits a localised regenerative immune response crucially dependent on rapid, transient release of the alarmin cytokine interleukin-33 (IL-33) by alveolar type 2 tumour cells. As a sentinel signal for Myc loss, IL-33 signalling reverses tumour immunosuppression and neoangiogenesis, critically recruits eosinophils, and promotes neoplastic cell elimination, driving regression beyond mere growth arrest. Notably, brief systemic recombinant IL-33 administration to mice with KRas/Myc-driven LUAD induces robust eosinophil influx and near-complete tumour resolution. Together, these findings demonstrate that blocking Myc activates an innate, tissue-intrinsic immune programme rooted in resolution of wound repair and capable of driving regression when activated in a tumour. This opens the possibility of treating cancer not only by blocking mitogenic oncogenic drivers but also by pro-actively triggering pro-resolution pathways.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Kortlever, R. M., Campos, T., Boeing, S., Uzwyshyn-Jones, K., Perfetto, A., Evan, G. I.. 2026-02-09. Targeting Myc activates a tissue-specific tumour resolution programme. https://doi.org/10.64898/2026.02.06.704498

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

An expanded, phenotypically distinct tumor cell subset with low HPV mRNA increases recurrence risk

Human papillomavirus-related (HPV+) cancers harbor a subset of tumor cells expressing certain senescence-related transcripts and reduced levels of HPV mRNAs. We aimed to define this HPV-low population's biologic traits and clinical significance via integrated analysis of recurrence-prone human HPV+ oropharyngeal cancers (OPCs) and patient-derived xenografts (PDXs) of variable therapy sensitivity. Single-cell mRNA sequencing of PDXs and human tumors detected gene expression profiles in HPV-low cells indicating lack of senescence or terminal differentiation and intact tumorigenic capacity. HPV-low cells in cisplatin-refractory PDXs and particular human OPCs differentially upregulated multiple pathways linked to aggressive tumor biology, including RAS signaling, IL-6 signaling, and EMT. Predicted loss of cell-cell interactions among HPV-low cells reflected reduced epithelial identity, further supporting their more aggressive biology. Accordingly, the size of the pre-treatment HPV-low fraction had strong, independent association with recurrence risk. Genetic subclones within OPCs varied widely in content of HPV-low cells, which were enriched in particular lineages. Our findings uncover novel pro-tumor functions of HPV-low cells and support a central role for them in therapy resistance as well as potential utility as a clinical biomarker. Further elucidating mechanisms of cooperativity and plasticity between HPV-low and high states holds promise to reveal targets in treatment-refractory HPV+ malignancies.

cancer biology↗

Discovery of molecular glues for modulating MHC presentation of cancer neoantigens

Antigen presentation by MHC class I molecules is essential for cancer immunosurveillance, but many cancer-specific antigens fail to form complexes with Class I MHC and are poorly presented on the cell surface. In this study, we present a chemical strategy to overcome this limitation by identifying peptide MHC glues (PMGs) that promote the formation of peptide-MHC complexes with otherwise unpresentable cancer antigens. Crystal structures of these complexes show that our compounds stabilize antigen-MHC binding by making simultaneous interactions with the MHC protein and the antigen peptides. These findings reveal a new approach for chemically rewiring Class I MHC antigen presentation and accessing rare cancer antigens for therapeutic targeting.

cancer biology↗

mRNA-LNP vaccination induces microenvironment remodeling and generation of tissue-resident memory T cells in glioblastoma

Glioblastoma remains highly refractory to immunotherapy, in part because of a profoundly immunosuppressive tumour microenvironment that limits effective T-cell responses. Although mRNA vaccines can induce anti-tumour immunity, how they reshape the glioblastoma immune ecosystem to support durable tumour control is not well understood. Here we use an immunocompetent EGFRvIII-driven syngeneic glioblastoma model and antigen-specific mRNA lipid nanoparticle (mRNA-LNP) vaccination to define the cellular and spatial mechanisms underlying therapeutic response. In our model, vaccination induced durable EGFRvIII-specific humoral and cellular immunity, resulting in complete tumour eradication and long-term protection against intracranial rechallenge. Integrative analyses incorporating flow cytometry, tumour interstitial fluid profiling, multiplex immunostaining, spatial transcriptomics and ligand-receptor modelling demonstrated extensive remodelling of the tumour microenvironment following vaccination. Early tumour control was associated with expansion of pro-inflammatory and antigen-presenting myeloid populations, increased cytotoxic CD8 T-cell infiltration and activation, enhanced interferon-responsive signalling, and the formation of immune-supportive spatial niches enriched for antigen presentation and chemokine-mediated cellular communication. Vaccination promoted inflammatory chemokine relay networks centred on the CXCL16-CXCR6 axis, a pathway linked to tissue residency programming in the central nervous system. Functional depletion studies identified CD4 and CD8 T cells as essential mediators of therapeutic efficacy, while durable protection was maintained by tumour-specific brain-resident memory CD8 T cells that persisted despite peripheral lymphocyte depletion. Together, these findings identify T-cell-driven microenvironmental remodelling as a critical mechanism linking mRNA vaccination to the establishment of long-term brain-resident anti-tumour immunity in glioblastoma.

cancer biology↗